Project Details

Early Career

Status: Funded - Open

A novel peanut allergy blood biomarker to predict anaphylaxis risk

Adam Collison, Ph.D.


BACKGROUND: Six to eight percent of children suffer from physician diagnosed food allergy, and the prevalence is increasing worldwide. Peanut allergy contributes 1–2% of childhood food allergies.Patients with peanut allergy are at the highest risk of a potentially life threatening reaction known as anaphylaxis affecting up to half of all individuals who are allergic to peanut.

GAP: Currently there is no effective test to predict the severity of allergic reaction to peanut in sensitized individuals.

HYPOTHESIS: That it is possible to predict severity of response to peanut using blood biomarkers.

METHODS: The proposed study will enroll peanut allergic individuals for an oral food challenge to be undertaken at John Hunter Children’s Hospital. Blood samples will be taken prior to food challenge to confirm the diagnostic validity of our blood biomarker as a predictor of peanut allergy and anaphylaxis. This study is required before the test can be adopted in clinically.

RESULTS: Pending

IMPACT: Successful completion of this study will be a significant breakthrough in the area of childhood food allergy. This will be the first report of a blood test capable of differentiating between allergic children who are at risk of a life-threatening anaphylactic response upon exposure to peanut vs less severe clinically significant allergy.

Website Link: http://www.hnekidshealth.nsw.gov.au/site/research-allergy

Supervising Institution:
Hunter Medical Research Institute

Joerg Mattes

Project Location:
New South Wales

Award Amount: